Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai And Takeda Strengthen Production System To Prepare For Possible Flu Pandemic

This article was originally published in PharmAsia News

Executive Summary

According to Japan Pharmaceutical Manufacturers Association's guidelines on flu pandemic preparation measures, which were upated last July, drug makers are responsible to continue providing drugs to patients. JPMA's guideline further calls 70 member companies to prepare drug supplies amid a flu pandemic that could last more than two months. Eisai has since increased dementia and cancer drug production in its seven factories worldwide, and assured a two month supply even if one of the factories stopped operation. Starting this year, Takeda plans to establish a system that will be able to produce two months of supply of all products in case Takeda's seven factories worldwide stop production for two months. (Click here for more - Japanese language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070003

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel